Shimomura A - Search Results

1

A retrospective single institutional analysis of outpatient chemotherapy in patients with cancer during the COVID-19 pandemic.

Shimanuki Y, Shimomura A, Ogawa C, Komuro M, Terakado H, Nishimura T, Shimizu C. Shimanuki Y, et al. Among authors: shimomura a. Glob Health Med. 2024 Aug 31;6(4):268-272. doi: 10.35772/ghm.2023.01134. Glob Health Med. 2024. PMID: 39219586 Free PMC article.

2

Are Platinum Drugs Ineffective for Triple-Negative Breast Cancer With Residual Invasive Disease After Neoadjuvant Chemotherapy?

Shimanuki Y, Shimomura A, Yoshimura K, Terakado H, Shimizu C. Shimanuki Y, et al. Among authors: shimomura a. J Clin Oncol. 2021 Nov 1;39(31):3521-3522. doi: 10.1200/JCO.21.01757. Epub 2021 Sep 23. J Clin Oncol. 2021. PMID: 34554850 No abstract available.

3

Who Can Receive the Benefit of a Palbociclib Add-On in Patients With HR+HER2- Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy?

Kawamura Y, Shimomura A, Shimizu C. Kawamura Y, et al. Among authors: shimomura a. J Clin Oncol. 2021 Sep 20;39(27):3089-3090. doi: 10.1200/JCO.21.01174. Epub 2021 Jul 6. J Clin Oncol. 2021. PMID: 34228507 No abstract available.

4

Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation?

Tanaka M, Shimomura A, Terakado H, Shimizu C. Tanaka M, et al. Among authors: shimomura a. J Clin Oncol. 2021 Nov 10;39(32):3647-3648. doi: 10.1200/JCO.21.01716. Epub 2021 Sep 10. J Clin Oncol. 2021. PMID: 34506214 No abstract available.

5

Cardiotoxicity of adjuvant chemotherapy with trastuzumab: a Japanese claim-based data analysis.

Ohtsu H, Shimomura A, Miyazaki S, Yonemoto N, Ueda S, Shimizu C, Sase K. Ohtsu H, et al. Among authors: shimomura a. Open Heart. 2022 Aug;9(2):e002053. doi: 10.1136/openhrt-2022-002053. Open Heart. 2022. PMID: 35995458 Free PMC article.

6

What Is the Optimal Way to Use Geriatric Assessment and Patient-Reported Outcomes in Older Patients With Advanced Cancer?

Kaneko T, Shimomura A, Shimizu C. Kaneko T, et al. Among authors: shimomura a. J Clin Oncol. 2023 May 10;41(14):2665-2666. doi: 10.1200/JCO.22.02874. Epub 2023 Mar 17. J Clin Oncol. 2023. PMID: 36930841 No abstract available.

7

Severe cytopenia during adjuvant chemotherapy for early breast cancer in a patient with idiopathic CD4+ lymphocytopenia.

Mimura K, Shimomura A, Watanabe K, Koda H, Nakayama K, Kitagawa D, Shimizu C. Mimura K, et al. Among authors: shimomura a. Oncol Lett. 2023 Jul 4;26(2):357. doi: 10.3892/ol.2023.13943. eCollection 2023 Aug. Oncol Lett. 2023. PMID: 37545613 Free PMC article.

8

Immunotherapy For US Patients With Metastatic Cancer at the End of Life.

Higashi H, Shimomura A, Shimizu C. Higashi H, et al. Among authors: shimomura a. JAMA Oncol. 2024 Aug 1;10(8):1133-1134. doi: 10.1001/jamaoncol.2024.1563. JAMA Oncol. 2024. PMID: 38842819 No abstract available.

9

Shorter Duration of Trastuzumab Combined With Chemotherapy for Early Breast Cancer.

Kusumoto M, Shimomura A, Shimizu C. Kusumoto M, et al. Among authors: shimomura a. J Clin Oncol. 2024 Sep 1;42(25):3061-3062. doi: 10.1200/JCO.23.02407. Epub 2024 Jun 24. J Clin Oncol. 2024. PMID: 38913973 No abstract available.

10

What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?

Ando K, Shimomura A, Yoshimura K, Kawamura Y, Shimizu C. Ando K, et al. Among authors: shimomura a. J Clin Oncol. 2021 Jun 10;39(17):1946-1947. doi: 10.1200/JCO.21.00178. Epub 2021 Apr 1. J Clin Oncol. 2021. PMID: 33793293 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

330 results

Search Page

Filters